News | January 28, 2022
Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
It meets stringent requirements for ensuring the safe storage and efficacy of temperature-sensitive vaccines, including those for Covid-19
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
New role strengthens Quantori’s global leadership position in data science & digital IT
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
The covid health center will be managed and administered by the district administration of Ballari
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Subscribe To Our Newsletter & Stay Updated
